IBM’s Two Bets Collide: A Quantum Acquisition Meets a Mainframe Hangover
Published on 07/26/2026 at 03:21 | Redaktion boerse-global.de
IBM’s stock staged a 3.74 percent recovery on Friday, closing at €188.38, but the bounce does little to mask the depth of the damage inflicted just days earlier. On Thursday, the shares plumbed a 52-week low of €175.14, leaving the stock down 27.52 percent since the start of the year. The trigger was a second-quarter earnings miss on July 22 that caught Wall Street off guard on both the top and bottom lines.
Revenue for the period came in at $17.2 billion, well short of the $17.9 billion analysts had penciled in. Adjusted earnings per share of $2.93 also missed the $3.01 consensus. The culprit was a 42 percent collapse in mainframe hardware sales, as the z17 system’s product cycle wound down. Chief Executive Arvind Krishna tried to frame the shortfall as a timing issue, arguing that roughly a third of the large deals that slipped past the June 30 cutoff had already closed in July. He described the weakness as “deferred, not lost” demand.
Yet the damage was compounded by a shift in customer behavior. In late June, enterprises began diverting spending away from traditional hardware toward AI servers and storage solutions, seeking to lock in prices ahead of anticipated increases. IBM responded by trimming its full-year revenue growth forecast to 4 to 5 percent at constant currencies, down from the previously guided “above 5 percent.”
The Quantum Card
Should investors sell immediately? Or is it worth buying IBM?
On July 23, the day after the earnings miss, IBM announced a binding agreement to acquire HRL Laboratories, a quantum-research institute previously co-owned by Boeing and General Motors. The deal, expected to close by the end of the third quarter, brings IBM expertise in silicon-spin qubit technology that complements its existing roadmap for superconducting quantum computers. Together with Anderon, a quantum-wafer foundry IBM launched in May, the acquisition forms a dual-pronged strategy aimed at fault-tolerant quantum systems.
The timing is conspicuous. With the mainframe business in freefall and consulting revenue stagnating, IBM is betting that its higher-margin software and quantum ventures can eventually decouple its valuation from the legacy hardware cycle. Boeing and GM have signaled they will continue collaborating with IBM on quantum applications post-close, a sign that at least some large customers remain engaged.
But the bull case rests on a leap of faith: that the margin-rich software and quantum units can scale fast enough to offset the structural decline in hardware. The average analyst price target of €231.06 implies 22.7 percent upside from Friday’s close, but that optimism is tempered by the stock’s technical position. The shares trade 17.61 percent below their 50-day moving average of €228.64 and 19.44 percent below the 200-day average of €233.84. The relative strength index sits at 35.5, nearing oversold territory after a 30-day decline of 18.63 percent.
Institutional Caution
Not everyone is buying the turnaround narrative. Unisphere Establishment trimmed its IBM stake by 13.1 percent in the first quarter, while the Bank of Nova Scotia cut its position by 29.2 percent. The moves suggest that some large holders are losing patience with the long lead time before quantum computing and AI generate meaningful revenue. The annualized 30-day volatility of nearly 85 percent underscores the market’s jitters.
On the bearish side, critics argue that the core business is eroding faster than the new units can grow. The mainframe collapse signals a structural shift in enterprise IT budgets away from legacy infrastructure, while specialized competitors are capturing an increasing share of AI spending. Heavy investment in quantum research and the Anderon foundry could weigh on cash flow before those technologies become commercially viable.
The Dividend Anchor
IBM at a turning point? This analysis reveals what investors need to know now.
For income-focused investors, IBM’s dividend remains a steadying force. The board approved a regular quarterly payout of $1.69 per share, payable on September 10 to shareholders of record as of August 10. That provides a floor of sorts, but it does little to address the fundamental question of whether IBM can reinvent itself before its legacy business fades.
What to Watch
The immediate test is whether the €175.14 low holds as support. If it does, the stock could enter a consolidation phase as the market digests the lowered growth outlook. The next catalyst is the HRL acquisition’s expected closing by the end of the third quarter, along with any regulatory updates. Meanwhile, earnings from cloud and enterprise-software rivals in the coming days will help set the tone for the broader tech sector.
Two bright spots bear watching: Red Hat, which grew 11 percent in the second quarter, and the newly integrated HashiCorp unit. Both need to demonstrate that IBM’s growth segments can absorb the hardware weakness. Until then, the stock remains caught between a quantum bet and a mainframe hangover, with the market waiting to see which bet pays off first.
Ad
IBM Stock: New Analysis - 26 July
Fresh IBM information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
